Poster Presentation of Non-Clinical Research Results on HM97662
Hanmi Pharmaceutical has laid the groundwork to enhance clinical efficacy by discovering new biomarkers for its next-generation targeted anticancer innovative drug, the 'EZH1/2 dual inhibitor (HM97662)'.
Poster of research results on HM97662 presented by Hanmi Pharmaceutical at the 24th Bio IT World Conference & Expo held in Boston, USA, from the 2nd to the 4th (local time). Hanmi Pharmaceutical
Hanmi Pharmaceutical announced on the 7th that it participated in the '24th Bio IT World Conference & Expo' held in Boston, USA, from the 2nd to the 4th (local time), where it presented research results on HM97662 in a poster session.
The EZH1 and EZH2 proteins, known as 'gene regulation switches,' play a crucial role in controlling cancer cell growth and differentiation. By simultaneously regulating these two proteins, effectively inhibiting the function of the cancer-causing protein complex called 'Polycomb Repressive Complex 2' can be expected to produce a powerful anticancer effect.
HM97662, through its mechanism of simultaneously inhibiting EZH2 and EZH1, possesses stronger efficacy and the potential to overcome resistance compared to EZH2 single-mechanism anticancer drugs. Currently, a global Phase 1 clinical trial is underway in South Korea and Australia to evaluate the safety and tolerability of HM97662 administered as a monotherapy to patients with advanced or metastatic solid tumors.
At this conference, Hanmi Pharmaceutical presented the possibility of contributing to predicting drug responsiveness and selecting suitable patients during the development process of the EZH1/2 dual inhibitor through a bioinformatics-based biomarker discovery strategy.
Until now, loss-of-function mutations in SWI/SNF complex constituent proteins have been used as biomarkers to predict responsiveness to EZH1/2 inhibitors. However, due to limitations such as incomplete predictive power, the need for alternative biomarker exploration has been raised.
Hanmi Pharmaceutical aimed to predict the responsiveness of the EZH1/2 dual inhibitor through a bioinformatics analysis workflow utilizing the public cancer cell dependency map database (DepMap) to discover new biomarkers.
Hanmi’s gene expression-based biomarker predictive power was validated in various preclinical tumor models and showed excellent performance in predicting the antitumor activity of HM97662 in multiple cancer types, including lung cancer, ovarian cancer, and esophageal cancer.
A Hanmi Pharmaceutical official stated, "HM97662 is a next-generation innovative drug that can precisely target not only cancer patients with specific gene mutations but also patient groups exhibiting specific gene expression patterns, going beyond the conventional synthetic lethality-based approach. We will continue to establish important evidence for developing precision treatment strategies for HM97662 through future research."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
